For the current study, Ranganath and colleagues reviewed records for all patients treated for RA at UCLA from 2018 to 2024, focusing on those with body mass index (BMI) values of at least 27 who received prescriptions for either semaglutide (Wegovy, Ozempic, Rybelsus) or tirzepatide (Mounjaro, Zepbound)
Controls on off-label uses, compounding, Rx/medical markers, and provider types
Clinical studies show 20% to 30% improvement in skin firmness after twelve weeks of topical use
Hyperpigmentation, uneven skin tone, and dark spots from breakouts are common skin problems in Bangladesh
625 NRD.E1 is a novel non-opioid therapeutic that is being developed for the treatment of PDPN
Hippocampal ripples down-regulate synapses